Atai Beckley N.V.

ATAISEC EDGAR

Pharmaceutical Preparations(P7)CIK: 1840904

Concept	FY2024	FY2023	FY2022	FY2021
Revenues	$314.0K	$233.0K	$20.4M	$0.00
Research and Development Expense	$2.0M	$2.8M	—	—
Operating Expenses	$125.8M	$145.0M	$156.2M	$104.2M
Operating Income (Loss)	-$125.5M	-$144.8M	-$135.8M	-$104.2M
Interest Expense	—	$923.0K	—	—
Nonoperating Income (Expense)	$86.2M	$9.6M	-$796.0K	$2.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$39.3M	-$135.2M	-$136.6M	-$101.8M
Income Tax Expense (Benefit)	$1.0M	$6.2M	$4.0M	$305.0K

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$293.5M	$305.4M	$414.2M	$111.5M
Assets, Current	$185.6M	$287.1M	$375.1M	$99.5M
Cash and Cash Equivalents, at Carrying Value	$45.0M	$190.6M	$362.3M	$97.2M
Liabilities	$49.2M	$39.7M	$28.2M	$16.2M
Liabilities, Current	$20.1M	$19.9M	$20.9M	$12.3M
Long-term Debt	$15.0M	$14.7M	$0.00	—
Accounts Payable, Current	$4.6M	$2.4M	$6.0M	$3.1M
Stockholders' Equity Attributable to Parent	$243.0M	$260.7M	$376.9M	$90.8M
Common Stock, Shares, Outstanding

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$84.1M	-$104.5M	-$63.2M	-$20.8M
Net Cash Provided by (Used in) Investing Activities	-$53.3M	-$86.8M	-$81.3M	-$28.3M
Net Cash Provided by (Used in) Financing Activities	-$8.4M	$20.8M	$409.9M	$113.1M
Payments to Acquire Property, Plant, and Equipment	$259.0K	$773.0K	$173.0K	$59.0K
Payments for Repurchase of Common Stock	$2.2M	$2.2M	$500.0K	$500.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)